Compare Rockwell Automation (ROK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs TG Therapeutics Inc — how do they compare? Rockwell Automation trades at $466.2 (market cap $51.04B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Rockwell Automation is far larger — about 6.2× TG Therapeutics Inc's market cap, and Rockwell Automation pays a 1.2% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ROK | TGTX | |
|---|---|---|
Market Cap | $51.04B | $8.26B |
Sector | Industrials | Health |
52-Week High | $495.08 | $59.06 |
52-Week Low | $328.67 | $26.39 |
Enterprise Value | $54.67B | $8.50B |
Dividend Yield | 1.2% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
